Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...
SALT LAKE CITY - Recursion (NASDAQ:RXRX) will present new clinical data from its ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP) during a company webinar scheduled ...
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...
The company laid out its restructuring plans in a regulatory document. These include a workforce reduction of around 20%. Before market open, Recursion disclosed in a tersely worded regulatory filing ...
Shares of Recursion Pharmaceuticals rose Tuesday morning after the company said slashing its workforce by 20% will extend its cash runway to the end of 2027. Shares were trading more than 10% higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results